New hope for tough lymphomas: experimental drug MDX2003 enters human testing
NCT ID NCT07249905
First seen Dec 11, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study tests an experimental drug called MDX2003 in about 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or not improved after at least two prior treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. The study is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Epworth HealthCare
RECRUITINGRichmond, Victoria, 3121, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.